How Often Does Neoadjuvant Chemotherapy Avoid Axillary Dissection in Patients With Histologically Confirmed Nodal Metastases? Results of a Prospective Study-Reference-Cited by-同舟云学术

How Often Does Neoadjuvant Chemotherapy Avoid Axillary Dissection in Patients With Histologically Confirmed Nodal Metastases? Results of a Prospective Study

Published:2016-05-09 Issue:11 Volume:23 Page:3467-3474
ISSN:1068-9265
Container-title:Annals of Surgical Oncology
language:en
Short-container-title:Ann Surg Oncol

Author:

Mamtani Anita,Barrio Andrea V.,King Tari A.,Van Zee Kimberly J.,Plitas George,Pilewskie Melissa,El-Tamer Mahmoud,Gemignani Mary L.,Heerdt Alexandra S.,Sclafani Lisa M.,Sacchini Virgilio,Cody Hiram S.,Patil Sujata,Morrow Monica

Funder

NIH/NCI Cancer Center Support Grant

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Surgery

Link

http://link.springer.com/content/pdf/10.1245/s10434-016-5246-8.pdf

Reference30 articles.

1. King TA, Morrow M. Surgical issues in patients with breast cancer receiving neoadjuvant chemotherapy. Nat Rev Clin Oncol. 2015;12:335–43.

2. Xing Y, Foy M, Cox DD, Kuerer HM, Hunt KK, Cormier JN. Meta-analysis of sentinel lymph node biopsy after preoperative chemotherapy in patients with breast cancer. Br J Surg. 2006;93:539–46.

3. Kelly AM, Dwamena B, Cronin P, Carlos RC. Breast cancer sentinel node identification and classification after neoadjuvant chemotherapy-systematic review and meta analysis. Acad Radiol. 2009;16:551–63.